IFNG and non-small cell lung carcinoma: Besides, Xiong et al. demonstrated that paclitaxel can augment Th1 cytokine (IFN-γ and IL-2) production in patients with advanced non-small cell lung cancer.[128] Flow cytometry data showed a significantly increased number of CD4+ IL-2+ T cells and CD8+ IFN-γ+ T cells among total lymphocytes after paclitaxel treatment (Figure 5C).